Know Cancer

forgot password

A Phase II Clinical and Translational Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Phase 2
18 Years
Open (Enrolling)
PANCREAS, Neuroendocrine

Thank you

Trial Information

A Phase II Clinical and Translational Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Inclusion Criteria:

- Patients with histologically or cytologically confirmed moderately to well
differentiated metastatic or unresectable carcinoid or islet cell tumors.

- Patient has at least one measurable lesion greater than or equal to 20 mm on CT or
MRI imaging.

- Patients who are on therapy with a somatostatin analog are eligible for entry but
must be on a stable dose for at least 3 months with no evidence of tumor shrinkage
during that time period.

- Patient ≥18 years of age on the day of signing informed consent.

- Patient has performance status 0-1 on the ECOG Performance Scale.

- Patient has adequate organ function as indicated by the following laboratory values:

- Absolute Neutrophil Count (ANC)≥1,500/mcL

- Platelets ≥100,000/mcL

- Hemoglobin ≥9 g/dL

- Serum Creatinine ≤2 times the upper limit of normal (ULN)/ OR calculated CrCl ≥60
mL/min (patients with creatinine levels ≥2 times the ULN only). Patient may not be on

- Serum total bilirubin ≤1.5 times the ULN

- AST (SGOT) and ALT (SGPT) ≤5 times the ULN

- HgbA1c ≤ 8%

- Fasting Glucose ≤120 mg/dl

- Creatinine clearance should be calculated by the Cockcroft-Gault method.Fasting is
defined as at least 4 hours without oral intake.

- Patient has voluntarily agreed to participate by giving written informed consent.

- Previous local therapy (e.g. chemoembolization or bland embolization) is allowed if
completed > 6 weeks or 5X half-life prior to study entry. For patients who received
local therapy prior to study entry, there must be either documented growth of
measurable disease within the embolization field or outside of the embolization
field, or both, prior to study entry if the area of the embolization field was the
only site of measurable disease.

- Previous chemotherapy, radiotherapy, and/or biologic therapy, including
investigational agents, is/are allowed if completed > 4 weeks prior to study entry
(>6 weeks if last regimen contained bevacizumab, BCNU or mitomycin C, and > 6 weeks
from last dose of radiation therapy or radiopharmaceutical.

- Patients must not have disease that is currently amenable to curative surgery. Prior
surgery is allowed no less than 6 weeks prior to study entry.

- Patients with diabetes mellitus are eligible for study entry but must have controlled
diabetes as defined by hemoglobin A1c <8.0% within 2 weeks of initiation of protocol

Exclusion Criteria:

- Patient has toxicities from prior therapies that have not resolved to grade 1 or
grade 0.

- Patient has known active CNS metastases and/or carcinomatous meningitis are excluded.
However, patients with CNS metastases who have completed a course of therapy would be
eligible for the study provided they are clinically stable for 1 month prior to entry
as defined as: (1) no evidence of new or enlarging CNS metastasis (2) off steroids
that are used to minimize surrounding brain edema.

- Patient has an active malignancy of metastatic potential other than the known
carcinoid or islet cell tumor, for the past 3 years.

- Patient has a known hypersensitivity to the components of study drug (MK-2206) or its
analogs that is not treatable by premedication with antihistamines and steroids.

- Patient has a condition, including but not limited to

- symptomatic congestive heart failure

- unstable angina pectoris

- serious cardiac arrhythmia

- history or current evidence of a myocardial infarction during the last 6 months,
and/or a current ECG tracing that is abnormal in the opinion of the treating

- QTc prolongation >450 msec (Bazett's formula)

- Patient with evidence of clinically significant bradycardia (HR <50), or a history of
clinically significant bradyarrhythmias such as sick sinus syndrome, 2nd degree AV
block (Mobitz Type 2).

- Patient with uncontrolled hypertension (i.e., 160/90 mHg SiBP). Patients who are
controlled on antihypertensive medication will be allowed to enter the study.

- Patient at significant risk for hypokalemia (e.g., patients on high dose diuretics,
or with recurrent diarrhea)

- Patient is a known diabetic who is poorly controlled (HBAc>8%)

- Patient has a history or current evidence of any condition, therapy, or lab
abnormality that might confound the results of the study, interfere with the
patient's participation for the full duration of the study, or is not in the best
interest of the patient to participate, in the opinion of the treating Investigator.

- Patient has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.

- Patient is, at the time of signing informed consent, a regular user (including
―recreational use‖) of any illicit drugs or had a recent history (within the last
year) of drug or alcohol abuse.

- Patient is pregnant or breastfeeding, or expecting to conceive or father children
within the projected duration of the study.

- Patient is known to be Human Immunodeficiency Virus (HIV)-positive

- Patient has known history of Hepatitis C or active Hepatitis A or B.

- Patient has symptomatic ascites or pleural effusion. A patient who is clinically
stable following treatment for these conditions is eligible.

- Patient has prior treatment with an mTOR inhibitor such as afinitor, sirolimus, or

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess overall response.

Outcome Time Frame:

every 12 weeks

Safety Issue:


Principal Investigator

Diane Reidy-Lagunes, MD,MS

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

July 2010

Completion Date:

July 2014

Related Keywords:

  • Pancreas
  • Neuroendocrine
  • MK-2206
  • Neuroendocrine Tumors
  • 10-067
  • Neuroendocrine Tumors



Memorial Sloan Kettering Cancer CenterNew York, New York  10021